NCT03914300 2026-04-13Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting11 enrolled 11 charts
NCT03690388 2025-09-25A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyExelixisPhase 3 Active not recruiting187 enrolled 13 charts 2 FDA